Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
LDLR- |
RCV000237951 | SCV000294918 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2016-03-25 | criteria provided, single submitter | literature only | |
Centre de Génétique Moléculaire et Chromosomique, |
RCV000237951 | SCV000503225 | likely pathogenic | Hypercholesterolemia, familial, 1 | 2016-12-16 | criteria provided, single submitter | clinical testing | subject mutated among 2600 FH index cases screened = 2 /FH-Corea |
Ambry Genetics | RCV003165666 | SCV003912562 | pathogenic | Cardiovascular phenotype | 2022-12-07 | criteria provided, single submitter | clinical testing | The c.694+1G>T intronic pathogenic mutation results from a G to T substitution one nucleotide after coding exon 4 of the LDLR gene. Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNAdecay; however, direct evidence is unavailable. The exact functional effect of the altered amino acid sequence is unknown; however, the impacted region is critical for protein function (Ambry internal data). This variant has been detected in an individual from a familial hypercholesterolemia (FH) cohort (Marduel M et al. Hum Mutat, 2010 Nov;31:E1811-24). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Another variant affecting this splice site (c.694+2T>C) has also been reported in association with FH (Gudnason V et al. Hum. Mutat., 1997;10:36-44). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |